Revicki D A, Leidy N K, Brennan-Diemer F, Thompson C, Togias A
Center for Health Outcome Research, MEDTAP International, Inc., Bethesda, MD 20814, USA.
Qual Life Res. 1998 Dec;7(8):693-702. doi: 10.1023/a:1008860113818.
The Rhinitis Symptom Utility Index (RSUI) was developed as a preference-based measure of rhinitis symptoms. The RSUI consist of ten questions on the severity and frequency of stuffy or blocked nose, runny nose, sneezing, itching, watery eyes and itching nose or throat over a 14 day period. A cross-sectional survey of 100 adults with allergic rhinitis was completed, with data collected on rhinitis history and severity, physician-rated rhinitis severity, the Rhinitis Quality of Life Questionnaire (RQLQ) and the Health Utilities Index Mark 2 (HUI2). The mean age of the patients was 37 +/- 11 years and 60% were female and 38% had a diagnosis of asthma. A multiplicative multiattribute utility function was developed from patient-derived preferences for different rhinitis-related symptom states. The mean RSUI score for this sample was 0.72 +/- 0.23, with a range of 0.15-1.0. Two week reproducibility of the RSUI was weak (ICC = 0.40). The index differentiated patients by physician-rated severity (p < 0.05) and was correlated 0.35 (p < 0.001) with the HUI2 and -0.67 (p < 0.001) with the RQLQ total score. The RSUI is brief and easy to administer and the results of this study support its reliability and validity. The modest reproducibility reflects the day to day variability of rhinitis. The RSUI may be a useful patient outcome for clinical trials and for cost-effectiveness studies comparing medical treatments for rhinitis.
鼻炎症状效用指数（RSUI）是作为一种基于偏好的鼻炎症状测量方法而开发的。RSUI由10个关于在14天内鼻塞或鼻堵塞、流鼻涕、打喷嚏、瘙痒、流泪以及鼻或喉瘙痒的严重程度和频率的问题组成。完成了一项对100名成人变应性鼻炎患者的横断面调查，收集了有关鼻炎病史和严重程度、医生评定的鼻炎严重程度、鼻炎生活质量问卷（RQLQ）以及健康效用指数2级（HUI2）的数据。患者的平均年龄为37±11岁，60%为女性，38%被诊断患有哮喘。根据患者对不同鼻炎相关症状状态的偏好开发了一个乘法多属性效用函数。该样本的平均RSUI评分为0.72±0.23，范围为0.15 - 1.0。RSUI的两周再现性较弱（组内相关系数ICC = 0.40）。该指数根据医生评定的严重程度区分患者（p < 0.05），与HUI2的相关性为0.35（p < 0.001），与RQLQ总分的相关性为 - 0.67（p < 0.001）。RSUI简短且易于实施，本研究结果支持其可靠性和有效性。适度的再现性反映了鼻炎的日常变异性。RSUI可能是临床试验以及比较鼻炎药物治疗的成本效益研究中一个有用的患者结局指标。
